Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heart Test Laboratories, Inc. - Warrant (NQ: HSCSW )

0.0359 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0359
Bid (Size) 0.0358 (29)
Ask (Size) 0.0600 (10)
Prev. Close 0.0359
Today's Range 0.0359 - 0.0359
52wk Range 0.0122 - 0.4500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
Granted Indian Patent for its MyoVista® Wavelet Technology 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease 
From Heart Test Laboratories, Inc.
Via GlobeNewswire

Performance

YTD
-60.07%
-60.07%
1 Month
+0.84%
+0.84%
3 Month
-28.20%
-28.20%
6 Month
-60.46%
-60.46%
1 Year
-74.14%
-74.14%

More News

Read More
HeartSciences to Present at the LD Micro Invitational XIV Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Adds Key Advisor to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Expands its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Appoints New Scientific Advisory Board Member
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.